Immunovant Inc.
24.29
1.41 (6.16%)
At close: Jan 15, 2025, 1:26 PM

Cashflow (Annual)

Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
Year FY24 FY23 FY22 FY21 FY20 FY19 FY18
Net Income -259.34M -210.96M -156.73M -107.43M -66.39M -28.60M -136.74M
Depreciation & Amortization 231.00K 193.00K 126.00K 65.00K 21.00K 10.00K n/a
Stock-Based Compensation 41.12M 32.30M 34.24M 18.82M 6.96M 1.31M 1.81M
Other Working Capital 1.41M 5.36M 10.52M 3.31M 3.84M -474.00K 1.44M
Other Non-Cash Items 1.13M 1.13M 1.11M 933.00K 1.24M -792.00K 5.19M
Deferred Income Tax n/a n/a n/a -282.00K n/a n/a n/a
Change in Working Capital 2.63M -10.85M 15.14M 4.57M 4.81M -474.00K 1.44M
Operating Cash Flow -214.23M -188.19M -106.11M -83.33M -53.36M -28.55M -128.30M
Capital Expenditures -360.00K -197.00K -254.00K -210.00K -31.00K -52.00K n/a
Acquisitions n/a n/a n/a n/a n/a n/a n/a
Purchase of Investments n/a n/a n/a n/a n/a n/a n/a
Sales Maturities Of Investments n/a n/a n/a n/a n/a n/a n/a
Other Investing Acitivies n/a n/a n/a n/a n/a n/a n/a
Investing Cash Flow -360.00K -197.00K -254.00K -210.00K -31.00K -52.00K n/a
Debt Repayment n/a n/a n/a n/a 37.91M n/a n/a
Common Stock Repurchased n/a n/a n/a n/a n/a n/a n/a
Dividend Paid n/a n/a n/a n/a n/a n/a n/a
Other Financial Acitivies -318.00K 385.00K 200.13M 383.11M 109.07M 35.58M 128.30M
Financial Cash Flow 472.43M 70.89M 200.13M 383.11M 146.97M 35.58M 128.30M
Net Cash Flow 258.83M -117.28M 93.67M 299.57M 93.59M 6.99M n/a
Free Cash Flow -214.59M -188.39M -106.37M -83.54M -53.39M -28.60M -128.30M